Stereotaxis plans to launch the MAGiC cardiac ablation catheter in early 2026, CEO and Chair David Fischel tells MassDevice.

Stereotaxis CEO David Fischel says the MAGiC catheter was designed "to overcome the natural limitations of manual pull-wire ...

The MAGiC catheter is designed to perform minimally invasive cardiac ablation procedures that treat various forms of ...

Stereotaxis’ CEO said the company has been “hampered clinically, commercially and strategically” by its prior dependence on a ...

Investing.com -- Stereotaxis (NYSE:STXS) stock surged 8.3% Tuesday after the surgical robotics company announced it received U.S. Food and Drug Administration (FDA) approval for its MAGiC Magnetic ...

CMS has approved electrophysiology ablation procedures for the ASC setting, marking a major advancement for outpatient cardiology and potentially accelerating the specialization of cardiac ASCs.

Untreated or unmanaged, SVT can lead to other possibly fatal heart abnormalities. Patients are advised to practice a cardiac-friendly diet and lifestyle (low sodium, little to no caffeine or alcohol, ...

A minimally invasive heart procedure to correct irregular heart rhythms called catheter ablation may reduce the risk of stroke enough that some patients can discontinue blood thinners, according to a ...

MONTREAL and CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of ...

Stereotaxis has won FDA approval for the MAGiC Magnetic Interventional Ablation Catheter. The device is a robotically ...

FDA approval of MAGiC is a significant milestone for Stereotaxis and the community of physicians pioneering robotics in electrophysiology. It ensures the benefits of Robotic Magnetic Navigation can ...